Metastatic Renal Cell Carcinoma: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management - Episode 7

Prognostic Value of Biomarkers in RCC

Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.

EP. 1: Trends in RCC Incidence
EP. 2: RCC Histologies
EP. 3: Risk Models and Prognostic Factors
EP. 4: Metastatic RCC: Prognosis and Recent Advances in Care
EP. 5: Biomarker Testing in RCC: Current Approaches
EP. 6: Biomarker Testing: Methodologies, Sample Types, and Emerging Data
Now Viewing
EP. 7: Prognostic Value of Biomarkers in RCC
EP. 8: The Role of Genetic Mutations in Prognosis and Decision-Making
EP. 9: Comparison of Older First-Line, Single-Agent Therapies
EP. 10: Newer First-Line Combination Therapy Options
EP. 11: Evolution of Combination Therapy As The Standard of Care
EP. 12: Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens
EP. 13: Safety and Efficacy Data: The CheckMate 214 Trial
EP. 14: Safety and Efficacy Data: The JAVELIN Renal 101 Trial
EP. 15: Safety and Efficacy Data: The KEYNOTE-426 Trial
EP. 16: Safety and Efficacy Data: The CheckMate 9ER Trial
EP. 17: Safety and Efficacy Data: The CLEAR Trial
EP. 18: Common Adverse Events with Single-Agent or Combination Therapy
EP. 19: Balancing Treatment Efficacy with Toxicity in Metastatic RCC
EP. 20: Strategies for Prevention and Management of Adverse Events
EP. 21: Patient-Specific Factors Impacting Treatment Choices in RCC
EP. 22: Considerations for Patient-Focused, Shared Decision-Making in RCC
EP. 23: Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
EP. 24: The Importance of Team-Based Management and Patient Communication